Clinical-stage biotechnology company Accro Bioscience Inc announced on Monday the closing of its USD50m Series C financing.
The round was led by OrbiMed, with participation from TCG Crossover, LAV, Cenova Capital, and existing investors Shenzhen Capital Group, and Oriza Holdings.
Accro Bioscience plans to use the proceeds from the financing to fund the Phase IIb clinical trial of AC-101, an RIPK2 inhibitor, for the treatment of Ulcerative Colitis (UC), and other novel therapeutic candidates for inflammatory and autoimmune diseases.
Whitehawk Therapeutics signs new option agreement for use of CPT113 linker-payload
Hims & Hers expands GLP-1 offering in Canada with generic semaglutide
Bayer's KERENDIA receives FDA priority review for type 1 diabetes and kidney disease treatment
Upsher-Smith launches generic Cyclosporine Ophthalmic Emulsion 0.05%
Hyundai Bioscience says XAFTY available for Ebola and Hantavirus treatment
4basebio secures clinical supply agreement for Phase II immunotherapy trial
FDA approves MEKanistic Therapeutics' IND for MTX-531
Matter Bio submits first IND application for Lm-LLO-TT
Myosin Therapeutics doses first patient in Phase 1/2 study of MT-125 in GBM
Accro Bioscience completes USD50m Series C financing
Dexcom launches Dexcom Flex CGM system for Type 2 diabetes patients in Germany
ImmunityBio secures US patent portfolio covering ANKTIVA combination therapy through to 2035
Artivion completes acquisition of Endospan following FDA approval of NEXUS Aortic Arch System
AstraZeneca wins US approval for Baxfendy as first aldosterone synthase inhibitor for hypertension